Skip to main content
SpringerLink
Log in

Intraperitoneal recombinant interferongamma in ovarian cancer patients with residual disease at second look laparotomy

  • Chapter
Ovarian Cancer 3

Abstract

Despite the improved overall response rate of debulking surgery and combination chemotherapy in advanced epithelial ovarian cancer, 60–70% of the patients have persistent disease at second look laparotomy [1,2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Piver, M.S. (ed.) (1987) Ovarian Malignancies: Diagnostic and Therapeutic Advances Churchill Livingstone, London, pp. 109–128.

    Google Scholar 

  2. Louie, K.G., Ozols, R.F., Myers, C.E. et al (1986) Long term results of a cis-platin containing combination chemotherapy regimen (Chex-up) for the treatment of advanced ovarian carcinoma. J. Clin. Oncol. 41579–85.

    PubMed  CAS  Google Scholar 

  3. Howell, W.B., Pleifle, C.E., Wung, W.E. et al (1983) Intraperitoneal cis-diaminedichloro- platinum with systemic thiosulfate protection. Cancer Res. 43,1426–31.

    PubMed  CAS  Google Scholar 

  4. Ten Bokkel Huinink, W.W., Dubbelman, R., Franklin, A. et al (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin. Oncol 12,43–6.

    PubMed  CAS  Google Scholar 

  5. Markman, M., Cleary, S., Lucas, W. et al (1986) IP chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin.Cancer Treat. Rep. 70755–60.

    PubMed  CAS  Google Scholar 

  6. Piver, M.S., Lele, S.B., Marchetti, D.L. et al (1988) Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J. Clin. Oncol 6,1679–84.

    PubMed  CAS  Google Scholar 

  7. Oldham, R.K. (1984) Biologicals and biological response modifiers: fourth modality of cancer treatment. Cancer Treat Rep 68, 221–3.

    PubMed  CAS  Google Scholar 

  8. Allavena, P., Grandi, M., DTncalci, M. et al (1987) Human tumor cell lines with pleiotropic drug resistance are efficiently killed by inter- leukin 2 activated killer cells and by activated monocytes. Int. J. Cancer 40104–7.

    Article  PubMed  CAS  Google Scholar 

  9. Berek, J.S., Hacker, N.F., Lichtenstein, A. et al (1985) Intraperitoneal recombinant alpha- interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer. Cancer Res 45 4447–53.

    PubMed  CAS  Google Scholar 

  10. Lembersby, B., Baldisseri, M., Kunscher, A. et al (1989) Phase I-II study of intraperitoneal (IP) low dose of interleukin-2 (IL-2) in refractory stage III ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol 8,636.

    Google Scholar 

  11. Bonnem, E.M. and Oldham, R.K. (1987) Gamma-interferon: physiology and speculation on its role in medicine. J. Biol Response Modif. 6 275–83.

    CAS  Google Scholar 

  12. Saito, T., Berens, M.E. and Welander, C.E. (1984) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 461142–7.

    Google Scholar 

  13. Balkwill, F., Ward, B., Moodie, E. and Fiers, W. (1987) Therapeutic potential of tumor factor-a and y-interferon in experimental human ovarian cancer. Cancer Res 474755–8.

    PubMed  CAS  Google Scholar 

  14. Malik, S.T.A., Knowles, R.G., East, N. et al (1991) Antitumor activity of gamma-interferon in ascitic and solid models of human ovarian cancer. Cancer Res 51 6643–9.

    PubMed  CAS  Google Scholar 

  15. Marth, C., Müller-Holzner, E., Greiter, E. et al (1990) Gamma interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50, 7037–41.

    PubMed  CAS  Google Scholar 

  16. Wallich, R., Bulbuc, N., Hammerling, G.J. et al (1985)Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315 301–3.

    Article  PubMed  CAS  Google Scholar 

  17. Tanaka, K., Hayashi, H., Hamada, C. et al (1986) Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of recognition of tumor cells. Proc. Natl Acad. Sci. USA 83 8723–7.

    Article  PubMed  CAS  Google Scholar 

  18. Weber, J., Jay, G., Tanaka, K. et al. (1987) Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166 1716–33.

    Article  PubMed  CAS  Google Scholar 

  19. Allavena, P., Peccatori, F., Maggioni, D. et al (1990) Intraperitoneal recombinant y-inter- feron in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50 7318–23.

    PubMed  CAS  Google Scholar 

  20. Mannel, D.N. and Falk, W. (1983) Interferon- gamma is required in activation of macrophages for cytotoxicity.Cell. Immunol 79 396–402.

    Article  PubMed  CAS  Google Scholar 

  21. Saito, T., Berens, M.E. and Welander, C.E. (1987) Characterisation of the indirect antitumor effects of y-interferon using ascites- associated macrophages in a human tumor clonogenic assay. Cancer Res 47 673–9.

    PubMed  CAS  Google Scholar 

  22. Colombo, N., Peccatori, F., Paganin, C. et al (1992) Antitumor and immunomodulatory activity of intraperitoneal interferon-gamma in ovarian carcinoma patients with minimal residual tumor after the chemotherapy. Int J. Cancer 5142–6.

    Article  PubMed  CAS  Google Scholar 

  23. Welander, C.E., Homesley, H.D., Reich, S.D. et al (1988) A Phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma.Am. J. Clin. Oncol II 455–60.

    Google Scholar 

  24. D’Acquisto, R., Markman, M., Hakes, T. et al (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma, J. Clin. Oncol 6, 689–95.

    PubMed  Google Scholar 

  25. Belardelli, F., Greser, I., Maury, C. and Maunoury, M.T. (1982) Antitumor effects of interferon in mice injected with interferonsensitive and interferon-resistant friend leukemia cells. Int. J Cancer 30 813–20.

    Article  PubMed  CAS  Google Scholar 

  26. Markman, M., Reichmann, B., Hakes, T. et al (1993) Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 71 1465–70.

    Article  Google Scholar 

  27. Berek, J.S., Hacker, N., Lichtenstein, A. et al (1985) Intraperitoneal immunotherapy of epithelial ovarian cancer with Corynebacterium parvum. Am. J. Obstet. Gynecol 1521003–9.

    PubMed  CAS  Google Scholar 

  28. Markman, M., Hakes, T., Reichman, B. et al (1991) Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma, J. Clin. Oncol 9204–10.

    PubMed  CAS  Google Scholar 

  29. Willemse, P., de Vries, E., Mulder, N. et al (1990) Intraperitoneal human recombinant interferon alpha 2b in minimal residual disease ovarian cancer. Eur. J.Cancer 26353–8.

    Article  PubMed  CAS  Google Scholar 

  30. Nardi, M., Cognetti, F., Pollera, C.F. et al (1990) Intraperitoneal recombinant alpha-2- interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer, J Clin. Oncol 8,1036–41.

    PubMed  CAS  Google Scholar 

  31. Berek, J.S., Welander, C., Schink, J. C. et al (1991) A Phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40 237–43.

    Article  PubMed  CAS  Google Scholar 

  32. Markman, M., Cleary, S., Lucas, W.E. et al (1986) Intraperitoneal chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin. Cancer Treat. Rep. 70 755–60.

    PubMed  CAS  Google Scholar 

  33. Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis, J.Clin. Oncol 9, 1668–74.

    Google Scholar 

  34. Markman, M., Reichman, B., Hakes, T. et al (1991) Responses to second-hne cisplatin- based intraperitoneal therapy in ovarian cancer: influence of prior response to intravenous cisplatin. J. Clin. Oncol 91801–5.

    PubMed  CAS  Google Scholar 

  35. Piccart, M., Speyer, J.L., Markman, M. et al (1985) Intraperitoneal chemotherapy: technical experiences at five institutions. Semin. Oncol 8,1618–29.

    Google Scholar 

  36. Lotze, M.T., Custer, M.C. and Rosenberg, S.A. (1986)Intraperitoneal administration of inter- leukin-2 in patients with cancer.Arch. Surg. 1211373–9.

    Article  PubMed  CAS  Google Scholar 

  37. Rambaldi, A., Introna, M., Colotta, F. et al (1985) Intraperitoneal administration of interferon ß in ovarian cancer patients. Cancer 56 294–301.

    Article  PubMed  CAS  Google Scholar 

  38. Elias, J. A., Jimenez, S.A. and Freundlich, B. (1987)Recombinant gamma, alpha, and beta interferons regulation of human lung fibroblast proliferation. Am. Rev. Respir. Dis. 135 62–5.

    PubMed  CAS  Google Scholar 

  39. Kähäri, V.M., Heino, J., Vuorio, T. and Vuorio, E. (1988) Interferon-of and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochem. Biophys. Acta 968 45–50.

    Article  PubMed  Google Scholar 

  40. Giri, S. N., Hyde, D.M. and Marafin, B.J. (1986) Ameliorating effect of murine gamma- interferon on bleomycin-induced lung collagen fibrosis in mice. Biochem. Med. Meth. Biol. 36,194–7.

    Article  CAS  Google Scholar 

  41. Granstein, R.D., Murphy, E.G., Margolis, R.G. et al. (1987) Gamma interferon inhibits collagen synthesis in vivo in the mouse J. Clin. Invest. 791254–8.

    Article  PubMed  CAS  Google Scholar 

  42. Björkholm, E., Petersson, F., Einhorn, N. et al (1982) Long term follow-up and prognostic factors in ovarian carcinoma: the Radiumhemmet series 1958–1973. Acta Radiol. Oncol. Radiat. Phys. Biol 21 413–19.

    Google Scholar 

  43. Lippman, S.M., Alberts, D.S. Slymen, D.J. et al (1988) Second look laparotomy in epithehal ovarian carcinoma. Cancer 61 2571–7.

    Article  PubMed  CAS  Google Scholar 

  44. De Gramont, A., Drolet, Y., Varette, C. et al (1989) Survival after second look laparotomy in advanced epithelial cancer. Eur.J. Cancer Clin. Oncol 25 251–7.

    Article  Google Scholar 

  45. Chambers, S.K., Chambers, J.T., Kohorn, E.I. et al (1988) Evaluation of the role of second look surgery in ovarian cancer. Obstet. Gynecol 72 404–8.

    PubMed  CAS  Google Scholar 

  46. Saito, T., Berens, M.E. and Welander, C.E. (1987) Interferon gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay. Cancer Chemother. Pharmacol 19233–9.

    Article  PubMed  CAS  Google Scholar 

  47. Mutch, D.G., Massard, S.L., Kao, M.S. and Collins, J.L. (1990) Proliferative and antiproliferative effects of interferon-7 and tumor necrosis factor-a on cell lines derived from cervical and ovarian malignancies.Am.J. Obstet. Gynecol 1631920–4.

    PubMed  CAS  Google Scholar 

  48. Maekawa, R., Kitagawa, T., Hojok, R. et al (1988) Differential efficacies of recombinant interferon y and recombinant human inter- leukin-2 against EL4-bearing mice. J Interferon Res. 8 241–9.

    Article  PubMed  CAS  Google Scholar 

  49. Silagi, S., Dutkowski, R. Schaeger, A. et al (1988) Eradication of mouse melanoma by combined treatment with recombinant human interleukin-2 and recombinant murine interferon gamma. Int. J. Cancer. 41 315–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Pujade-Lauraine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Francois
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Fumoleau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Monnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. A. Nooy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Mignot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Bugat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. M. D. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Mousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G. Netter
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F. Maloisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S. Larbaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P. Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M. Brandely
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynaecology, Northern General Hospital, Sheffield University, Sheffield, UK

    Frank Sharp  & Tony Blackett  & 

  2. The Samaritan Hospital for Women, St Mary’s Hospital Medical School, London, UK

    Peter Mason

  3. Division of Gynecologic Oncology, UCLA School of Medicine, Los Angeles, USA

    Jonathan Berek

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Chapman & Hall

About this chapter

Cite this chapter

Pujade-Lauraine, E. et al. (1995). Intraperitoneal recombinant interferongamma in ovarian cancer patients with residual disease at second look laparotomy. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-0136-4_24

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-0138-8

  • Online ISBN: 978-1-4757-0136-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation